CBD Life Sciences Inc. (CBDL) Announces New Powerful 500MG THC Delta-8 Gummy
CBD Life Sciences (CBDL) has announced the launch of a new 500MG Delta-8 THC gummy product, expanding its cannabinoid wellness portfolio. The lab-tested gummies, available in Blue Razz & Strawberry flavors, are manufactured in-house and will be sold through www.thecbdvault.com. The product launch aligns with growing Delta-8 market projections, expected to reach $2.1 billion by 2026.
The gummies are designed to offer various wellness benefits, including pain relief, anxiety and stress support, nausea control, appetite stimulation, and potential neuroprotective effects. Unlike Delta-9 THC, Delta-8 provides a milder psychoactive experience. Each batch undergoes independent lab testing to ensure purity, potency, and compliance.
CBD Life Sciences (CBDL) ha annunciato il lancio di un nuovo prodotto di gummies al Delta-8 THC da 500MG, ampliando il suo portafoglio di benessere a base di cannabinoidi. Le caramelle gommose, testate in laboratorio e disponibili nei gusti Blue Razz e Fragola, sono prodotte internamente e saranno vendute tramite www.thecbdvault.com. Il lancio del prodotto è in linea con le crescenti previsioni di mercato per il Delta-8, che si prevede raggiungerà un valore di 2,1 miliardi di dollari entro il 2026.
Le gummies sono progettate per offrire diversi benefici per il benessere, tra cui sollievo dal dolore, supporto per ansia e stress, controllo della nausea, stimolazione dell’appetito e potenziali effetti neuroprotettivi. A differenza del Delta-9 THC, il Delta-8 offre un’esperienza psicoattiva più leggera. Ogni lotto viene sottoposto a test di laboratorio indipendenti per garantire purezza, potenza e conformità.
CBD Life Sciences (CBDL) ha anunciado el lanzamiento de un nuevo producto de gomitas de Delta-8 THC de 500MG, ampliando su portafolio de bienestar con cannabinoides. Las gomitas, probadas en laboratorio y disponibles en sabores Blue Razz y Fresa, se fabrican internamente y se venderán a través de www.thecbdvault.com. El lanzamiento del producto coincide con las crecientes proyecciones del mercado de Delta-8, que se espera alcance los 2.1 mil millones de dólares para 2026.
Las gomitas están diseñadas para ofrecer diversos beneficios para el bienestar, incluyendo alivio del dolor, apoyo contra la ansiedad y el estrés, control de náuseas, estimulación del apetito y posibles efectos neuroprotectores. A diferencia del Delta-9 THC, el Delta-8 proporciona una experiencia psicoactiva más suave. Cada lote pasa por pruebas de laboratorio independientes para garantizar pureza, potencia y cumplimiento.
CBD 라이프 사이언스(CBDL)는 새로운 500MG 델타-8 THC 구미 제품을 출시하여 카나비노이드 웰니스 포트폴리오를 확장한다고 발표했습니다. 실험실 테스트를 거친 이 구미는 블루 래즈 및 딸기 맛으로 제공되며 자체 생산되어 www.thecbdvault.com을 통해 판매될 예정입니다. 이번 제품 출시는 2026년까지 21억 달러에 이를 것으로 예상되는 델타-8 시장 성장 전망과 맞물려 있습니다.
이 구미는 통증 완화, 불안 및 스트레스 지원, 메스꺼움 조절, 식욕 촉진, 잠재적인 신경 보호 효과 등 다양한 웰니스 혜택을 제공하도록 설계되었습니다. 델타-9 THC와 달리 델타-8은 더 부드러운 향정신성 경험을 제공합니다. 각 배치는 순도, 효능 및 규정 준수를 보장하기 위해 독립적인 실험실 테스트를 거칩니다.
CBD Life Sciences (CBDL) a annoncé le lancement d'un nouveau produit de gummies Delta-8 THC 500MG, élargissant ainsi son portefeuille de bien-être à base de cannabinoïdes. Ces gummies testés en laboratoire, disponibles aux saveurs Blue Razz et Fraise, sont fabriqués en interne et seront vendus via www.thecbdvault.com. Ce lancement de produit s'aligne sur les projections croissantes du marché du Delta-8, qui devrait atteindre 2,1 milliards de dollars d'ici 2026.
Les gummies sont conçus pour offrir divers bienfaits pour le bien-être, notamment le soulagement de la douleur, le soutien contre l'anxiété et le stress, le contrôle des nausées, la stimulation de l'appétit et des effets neuroprotecteurs potentiels. Contrairement au Delta-9 THC, le Delta-8 procure une expérience psychoactive plus douce. Chaque lot fait l'objet de tests en laboratoire indépendants pour garantir pureté, puissance et conformité.
CBD Life Sciences (CBDL) hat die Einführung eines neuen 500MG Delta-8 THC Gummibärchens angekündigt und erweitert damit sein Portfolio im Bereich Cannabinoid-Wellness. Die laborgeprüften Gummibärchen sind in den Geschmacksrichtungen Blue Razz und Erdbeere erhältlich, werden intern hergestellt und über www.thecbdvault.com verkauft. Die Produkteinführung entspricht den wachsenden Marktprognosen für Delta-8, die bis 2026 voraussichtlich 2,1 Milliarden US-Dollar erreichen werden.
Die Gummibärchen sind darauf ausgelegt, verschiedene Wellness-Vorteile zu bieten, darunter Schmerzlinderung, Unterstützung bei Angst und Stress, Übelkeitskontrolle, Appetitanregung und potenzielle neuroprotektive Wirkungen. Im Gegensatz zu Delta-9 THC bietet Delta-8 ein milderes psychoaktives Erlebnis. Jede Charge wird unabhängig im Labor getestet, um Reinheit, Wirksamkeit und Konformität sicherzustellen.
- Product expansion in high-growth Delta-8 market projected to reach $2.1B by 2026
- In-house manufacturing and lab testing ensures quality control and higher margins
- Delta-8 products are already one of CBDL's strongest performing categories
- Operating in a highly competitive and regulated cannabinoid market
- Potential regulatory risks associated with Delta-8 THC products
- Limited distribution channel through single website
With Delta-8 product revenue continuing to climb, CBDL introduces a lab-tested gummy formulation to meet surging demand in a market projected to exceed
SCOTTSDALE, AZ / ACCESS Newswire / May 28, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a rising force in the cannabinoid wellness industry, is proud to announce the latest addition to its growing Delta-8 product lineup: a premium, lab-tested Delta-8 THC gummy, developed in-house to ensure consistency, potency, and quality at every step.
Building on the success of its existing Delta-8 offerings, this new gummy marks another strategic milestone in CBDL's mission to dominate the cannabinoid edibles market. Crafted in a controlled lab environment, this new edible is designed for consumers who prioritize quality, effectiveness, and a clean, smooth Delta-8 experience.
"We've already seen strong performance across our Delta-8 line, and this gummy is a direct response to customer demand for more convenient, enjoyable, and effective ways to experience its benefits," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "As always, we're delivering a product that's backed by science, produced in-house, and driven by results."
Delta-8 THC: Expanding the Future of Functional Wellness
Unlike traditional Delta-9 THC, Delta-8 offers a milder, clearer psychoactive experience - making it a preferred option for wellness seekers, first-time users, and individuals looking for a balanced high without anxiety.
CBDL's newly formulated Delta-8 gummies are not just about effect - they're designed to deliver real therapeutic value. Below is a breakdown of the core wellness benefits supported by research and consumer feedback:
Pain Relief
• Engages the endocannabinoid system to help regulate pain
• May reduce inflammation that contributes to chronic discomfort
Anxiety & Stress Support
• Natural calming effects to help manage daily stress and reduce anxiety
• Promotes overall mood balance without sedation
Nausea Control
• Anti-emetic potential makes it a powerful option for those undergoing chemotherapy or other nausea-inducing treatments
Appetite Stimulation
• Ideal for individuals with appetite loss or dietary imbalances related to health conditions
Neuroprotective Potential
• Early research suggests Delta-8 THC may contribute to long-term brain health through its interaction with CB1 receptors
Made In-House. Backed by Lab Testing.
Unlike many mass-produced gummies on the market, CBDL maintains full control over every phase - from formulation to packaging - in its in-house manufacturing facility. Each batch is independently lab-tested to guarantee purity, potency, and compliance, giving consumers complete confidence in what they're consuming.
Strategic Growth for Shareholders & Stakeholders
Delta-8 THC products have already proven to be one of CBDL's strongest performing categories, and this launch further solidifies the company's aggressive expansion in the high-growth cannabinoid edible space. The market for Delta-8 continues to gain national momentum, with sales projections showing compound annual growth that far outpaces many traditional supplement sectors.
"This gummy is just one part of a much larger product ecosystem we're building - focused on in-demand cannabinoids, real health outcomes, and market scalability," said Nelson.
Product Details
• Product: Delta-8 THC Gummy
• Type: Vegan, In-House Formulated, Lab-Tested
• MG per Gummy: 500MG
• Availability: Launching via www.thecbdvault.com
• Flavors: Blue Razz & Strawberry
About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is a vertically integrated health and wellness company focused on cannabinoid innovation. With a robust pipeline of CBD, Delta-8, and other hemp-derived formulations, CBDL operates across direct-to-consumer, retail, and wholesale channels - including recent distribution on Walmart Marketplace and additional platforms coming soon.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on ACCESS Newswire
FAQ
What is the strength of CBDL's new Delta-8 THC gummy?
How does CBDL ensure the quality of their Delta-8 gummies?
What are the main benefits of CBDL's Delta-8 THC gummies?
How is Delta-8 THC different from traditional Delta-9 THC?
Where can customers purchase CBDL's new Delta-8 gummies?
